TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33081817
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with macrolide azithromycin and hydroxychloroquine
Study: 34322703
Drug: Venetoclax plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax plus low-dose cytarabine
Study: 35255426
Drug: Cyanidin‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanidin‐ and delphinidin‐rich extract (CDRE) providing 320.4 mg of anthocyanins (90% cyanidin and delphinidin)
Study: 33958495
Drug: Vibroacoustic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibroacoustic therapy using the VITAFON-2 apparatus
Study: 35737102
Drug: Group iSLN:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group iSLN: bilateral perineural injection with 4 mg dexamethasone around the internal branch of superior laryngeal nerve
Study: 35737102
Drug: Group Spray:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Spray: 4 mg dexamethasone sprayed on the vocal cord
Study: 33258032
Drug: Stent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent treatment
Study: 35219356
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with fluvoxamine
Study: 35485333
Drug: Rilpivirine plus
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine plus darunavir/cobicistat (25 mg rilpivirine plus 800/150 mg darunavir/cobicistat once daily)
Study: 35485333
Drug: Standard three-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard three-drug therapy (late switch group)
Study: 33691730
Drug: Diuretic (furosemide)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diuretic (furosemide)
Study: 33646835
Drug: Oxford/AstraZeneca vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxford/AstraZeneca vaccine (ChAdOx1 nCoV‐19)
Study: 36136951
Drug: Bifiform Kids
Normalized name: Mederma for Kids
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bifiform Kids (2 chewable tablets twice per day for 21 days)
Study: 34116393
Drug: Magnesium treatment
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium treatment for 12 weeks
Study: 33009185
Drug: Rectus sheath
Normalized name: Sus scrofa rectum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectus sheath block (RSB) with 2 mg/kg of levobupivacaine
Study: 33009185
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with 12.5 mg hyperbaric bupivacaine and 0.5 mg diamorphine
Study: 36057030
Drug: Rebaudioside A
Normalized name: Rebaudioside A
DrugBank: Rebaudioside A (DB15136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebaudioside A (3 g)
Study: 36690404
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) infusion
Study: 34339618
Drug: Clonidine (CLON)
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine (CLON) infusion
Study: 32461053
Drug: Topical ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ivermectin (0.1%)‐metronidazole (1%) gel treatment
Study: 32633244
Drug: Manosar® (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manosar® (2 g of d-mannose + 140 mg of proanthocyanidins)
Study: 32633244
Drug: Isolated PAC
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated PAC (240 mg of continuous-release proanthocyanidins)
Study: 35042152
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, every 3 weeks)
Study: 33217335
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg and 25 mg)
Study: 34233727
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with TNFi plus MTX
Study: 34233727
Drug: Switched therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched therapy with tacrolimus (TAC) plus MTX
Study: 34233727
Drug: Switched therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched therapy with TAC plus MTX
Study: 34849920
Drug: Standard in
Normalized name: Standard infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard in vitro fertilization (IVF) with flexible GnRH antagonist protocol and hCG as ovulatory trigger
Study: 33655380
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab 2 mg/kg at Weeks 0, 4, then every 8 weeks through Week 52
Study: 35241023
Drug: Intravenous Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tranexamic acid (TXA)
Study: 32521015
Drug: diacerein 50
Normalized name: Diacerein 50 mg and glucosamine sulfate potassium chloride 1.5 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: diacerein 50 mg once daily for 1 month and twice daily thereafter (n=140)
Study: 32521015
Drug: celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 200 mg once daily (n=148)
Study: 32640842
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (Humalog®)
Study: 32978185
Drug: Critical care
Normalized name: Adult critical care formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critical care telehealth program (daily telemedical rounds at ICU)
Study: 34590519
Drug: Indacaterol/glycopyrronium (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg
Study: 34118635
Drug: Psychotropic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medication (long-term use)
Study: 34118635
Drug: Antidepressants plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants plus lithium (long-term use)
Study: 34118635
Drug: Antipsychotics (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics (long-term use)
Study: 34118635
Drug: Brief psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychological therapy (ASSIP) added to medication
Study: 32027542
Drug: Heated-water exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated-water exercise therapy (HWET) for 12 weeks
Study: 32027542
Drug: Land-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-based exercise therapy (LBET) for 12 weeks
Study: 32027542
Drug: Heated-water exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated-water exercise therapy (HWET)
Study: 32027542
Drug: Land-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-based exercise therapy (LBET)
Study: 33862001
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg tablets twice per day for up to 2 years)
Study: 35502234
Drug: Liposomal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal drugs for cancer therapy
Study: 32033103
Drug: Caffeine 3
Normalized name: caffeine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 3 mg/kg/b.m.
Study: 32033103
Drug: Caffeine 6
Normalized name: caffeine 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 6 mg/kg/b.m.
Study: 32033103
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 and 6 mg/kg/b.m.)
Study: 34795281
Drug: PPQ level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPQ level of 15.4 ng/mL
Study: 35545388
Drug: Development and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development and Well‐Being Assessment SDA tool as an adjunct to usual clinical care
Study: 34260693
Drug: Endoscopic eradication
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic eradication therapy (EET)
Study: 34645661
Drug: Specialised outpatient
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialised outpatient treatment in CAG Bipolar
Study: 34645661
Drug: Generalised community‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generalised community‐based outpatient treatment
Study: 33208330
Drug: Semantic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantic treatment for lexical retrieval deficits in the optimal language determined by the BiLex model.
Study: 33208330
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving treatment in the language opposite to the model's recommendation.
Study: 34182611
Drug: AZD8154 inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8154 inhaled doses (0.1–7.7 mg)
Study: 34182611
Drug: AZD8154 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8154 IV infusion (0.15 mg)
Study: 34182611
Drug: AZD8154 inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8154 inhaled doses (0.6, 1.8, and 3.1 mg) with once-daily dosing on Days 4–12
Study: 34182611
Drug: AZD8154 inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8154 inhaled route
Study: 37470445
Drug: No study
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study drug (control)
Study: 34001174
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (1 to 2 units of 200 to 250 ml) along with local standard treatment
Study: 37018790
Drug: Local standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local standard treatment alone
Study: 33905041
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (0.25 g)
Study: 33905041
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (20.0 g) with vitamin C (0.25 g)
Study: 33905041
Drug: Placebo (20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20.0 g of white rice flour) with vitamin C (0.25 g)
Study: 32728763
Drug: Breast augmentation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast augmentation with various implant volumes and textures
Study: 35906581
Drug: Family-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based cognitive behavioural therapy (CBT)
Study: 35906581
Drug: Family-based relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based relaxation therapy
Study: 32665656
Drug: Epinephrine group
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine group (5 mcg ml-1, n=41)
Study: 32570252
Drug: Tofacitinib (JAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (JAK inhibitor)
Study: 32570252
Drug: Filgotinib and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib and upadacitinib (JAK inhibitors)
Study: 32570252
Drug: Vedolizumab (α4β7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (α4β7 integrin inhibitor)
Study: 32570252
Drug: AJM300 (α4-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: AJM300 (α4-specific small molecule)
Study: 32570252
Drug: PF-00547659 (antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00547659 (antibody against endothelial MadCAM-1)
Study: 32570252
Drug: Ozanimod (S1PR1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod (S1PR1 and S1PR5 inhibitor)
Study: 34968730
Drug: Dose-escalated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated group (initially 15 mg QD, escalated to 30 mg QD if lost response)
Study: 34968730
Drug: Dose-escalated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated group
Study: 33876196
Drug: Choline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline (500 mg/d)
Study: 36302173
Drug: Cediranib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib (30 mg)
Study: 34851253
Drug: Medicine journals
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine journals (median impact factor 25.0)
Study: 34851253
Drug: Medicine papers
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine papers
Study: 33239018
Drug: Cases (received
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cases (received HIV prevention services and enrolled in a 12‐month simulated vaccine efficacy trial using Hepatitis B vaccine)
Study: 36154509
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (ITD2) (5 mg/ml)
Study: 36154509
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (ITD1) (2 mg/ml)
Study: 32271467
Drug: 1-mL PRGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mL PRGF injections
Study: 32271467
Drug: 1-mL lidocaine
Normalized name: 0.1 ML Lidocaine Hydrochloride 1 % Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mL lidocaine injections
Study: 36263928
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 100 U/ml (IDeg-100)
Study: 34637858
Drug: Midazolam (0.0125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.0125 mg.kg-1)
Study: 34637858
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo solution)
Study: 34549720
Drug: HFNC oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC oxygen therapy
Study: 34549720
Drug: Nasal cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannula oxygen therapy
Study: 33871015
Drug: Daily motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily motivational text messages
Study: 32017373
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (no manipulation of IOL orientation)
Study: 34558847
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) 650 mg twice per day (1.3 g/day) for 4 days, followed by 650 mg on the morning of day 5.
Study: 32299512
Drug: Brief psychiatric
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychiatric treatment (10 sessions over 4 months)
Study: 34907265
Drug: Ranibizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (2 mg/0.05 ml) administered via 3 intravitreal injections at approximately 30-day intervals
Study: 36315274
Drug: Low dialysate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dialysate sodium (135 mmol/L)
Study: 36315274
Drug: Standard dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysate sodium (138 mmol/L)
Study: 35099566
Drug: Continuously migrating
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuously migrating TKAs (9 implants)
Study: 36241349
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement treatment (HT)
Study: 34157994
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (self-monitoring of daily steps plus counseling)
Study: 32340904
Drug: Leucine-rich supplement
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine-rich supplement in combination with nutrition and physical exercise program
Study: 34968819
Drug: Early oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oxytocin infusion following amniotomy
Study: 34968819
Drug: Delayed oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed oxytocin infusion following amniotomy
Study: 32646638
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker prescribed at discharge
Study: 32646638
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy prescribed
Study: 32375905
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg d-cycloserine (DCS)
Study: 35560310
Drug: Cocoa-based flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa-based flavanols (FLV; 900 mg/d)
Study: 33900204
Drug: Internet-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based intervention for CVD management including medication and CVD risk data from EHR, personalized risk score estimation, goal setting, self-monitoring, social forum, heart health messages.
Study: 35927020
Drug: Disadvantage indices
Normalized name: Advantage Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disadvantage indices for vaccine allocation
Study: 32643966
Drug: Other nonsteroidal
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other nonsteroidal anti-inflammatory drugs
Study: 36380117
Drug: Soccer League
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soccer League (SL) intervention with 778 men attending soccer three times weekly for 6 months (72 sessions; 94% uptake, 45.5% weekly attendance rate) combined with an HIV/substance use cognitive-behavioral intervention.
Study: 36380117
Drug: Control Condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Condition (CC) with 415 men receiving educational materials and referrals at 3 month intervals.
Study: 32409944
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without bevacizumab (Non-BEV)
Study: 32409944
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) treatment in first order recurrence
Study: 32409944
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without bevacizumab (Non-BEV) in first order recurrence
Study: 32409944
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) treatment in second or higher order recurrence
Study: 32409944
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without bevacizumab (Non-BEV) in second or higher order recurrence
Study: 33932804
Drug: Sardine group
Normalized name: sardine allergenic extract
DrugBank: European pilchard (DB10622)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sardine group (SG) - 200 g of sardine per week
Study: 32601978
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (participants recalled other recently consumed foods to increase salience of dietary variety)
Study: 35843287
Drug: Clear fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear fluids + 2 L of polyethylene glycol (PEG) 12 hours before CE (Arm B)
Study: 35843287
Drug: Clear fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear fluids + 1 L PEG + sodium ascorbate 3 hours before CE (Arm C)
Study: 32140989
Drug: Short-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course antibiotic therapy (≤ 10 days)
Study: 32140989
Drug: Long-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course antibiotic therapy (28 days)
Study: 33040829
Drug: Guizhi Fuling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guizhi Fuling Pills (L, M, H groups)
Study: 36304175
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral saline administration (5 mL·kg−1 of normal saline 2 hours before anesthesia)
Study: 616774896
Drug: Vestibular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vestibular electrical stimulation (VES) combined with medical treatment; 30 min long, twice a day, three times a week, for 12 sessions at 80 Hz TENS.
Study: 616774896
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment only (control group).
Study: 35901339
Drug: Curcumin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (800 mg twice daily)
Study: 616062932
Drug: Eicosapentaenoic (EPA)
Normalized name: eicosapentaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eicosapentaenoic (EPA) and docosahexaenoic (DHA) polyunsaturated fatty acids supplementation (2.4g/d, 1.6 g EPA and 0.8 g DHA, ratio 2:1)
Study: 33865303
Drug: LDC cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDC cream (3% Defensil®, 5% dexpanthenol and ceramide)
Study: 33865303
Drug: LDC cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDC cream
Study: 35535242
Drug: Ultrasound-guided QLB
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided QLB with 20 ml of 0.375% ropivacaine
Study: 36373323
Drug: NIR light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR light treatment (1060-1080 nm and 800-820 nm) for 12 weeks
Study: 36027980
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity
Study: 32498216
Drug: Difensil Immuno
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difensil Immuno (DI) 10 mL for 90 days
Study: 32498216
Drug: Difensil Immuno
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difensil Immuno (DI) 15 mL for 45 days